Prot: OPN-FLU-CS-3205: A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 μg of OPN-375 Twice a Day (BID) in Subjects with Chronic Sinusi

Project: Research project

Project Details

Effective start/end date6/12/196/30/23


  • Covance Inc. (Prot: OPN-FLU-CS-3205)
  • OptiNose US Inc. (Prot: OPN-FLU-CS-3205)